` ANRO (Alto Neuroscience Inc) vs S&P 500 Comparison - Alpha Spread

A
ANRO
vs
S&P 500

Over the past 12 months, ANRO has significantly outperformed S&P 500, delivering a return of +400% compared to the S&P 500's +14% growth.

Stocks Performance
ANRO vs S&P 500

Loading
ANRO
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ANRO vs S&P 500

Performance Gap Between ANRO and GSPC
HIDDEN
Show

Performance By Year
ANRO vs S&P 500

Loading
ANRO
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Alto Neuroscience Inc vs Peers

S&P 500
ANRO
539112
SLB
RDDT
BKR
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Alto Neuroscience Inc
Glance View

Market Cap
620.8m USD
Industry
N/A

Alto Neuroscience Inc is a US-based company operating in industry. The company is headquartered in Los Altos, California. The company went IPO on 2024-02-02. Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. Through insights derived from the Company’s scalable and proprietary Precision Psychiatry Platform, which applies rigorous data science and robust analytics to data gathered by neurocognitive assessments, electroencephalography, and wearable devices, the Company aims to discover brain-based biomarkers to better identify which patients are more likely to respond to its novel product candidates. Its pipeline consists of five clinical-stage assets, such as ALTO-100, ALTO-202, ALTO-300, ALTO-101, and ALTO-203, which target depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers. Its pipeline also includes novel drug candidates in depression, post-traumatic stress disorder (PTSD), and other mental health conditions.

ANRO Intrinsic Value
Not Available
Back to Top